Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

ClinicalTrials.gov ID: NCT03611582

Public ClinicalTrials.gov record NCT03611582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity

Study identification

NCT ID
NCT03611582
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
611 participants

Conditions and interventions

Interventions

  • Placebo (semaglutide) Drug
  • Semaglutide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2018
Primary completion
Mar 17, 2020
Completion
Apr 27, 2020
Last update posted
Nov 10, 2021

2018 – 2020

United States locations

U.S. sites
41
U.S. states
17
U.S. cities
39
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35294
Novo Nordisk Investigational Site Montgomery Alabama 36106
Novo Nordisk Investigational Site Peoria Arizona 85381
Novo Nordisk Investigational Site Anaheim California 92801
Novo Nordisk Investigational Site Escondido California 92025
Novo Nordisk Investigational Site Fresno California 93720
Novo Nordisk Investigational Site Fullerton California 92835
Novo Nordisk Investigational Site Huntington Beach California 92648
Novo Nordisk Investigational Site Los Angeles California 90057
Novo Nordisk Investigational Site Walnut Creek California 94598
Novo Nordisk Investigational Site Golden Colorado 80401
Novo Nordisk Investigational Site Kissimmee Florida 34744
Novo Nordisk Investigational Site Panama City Florida 32401
Novo Nordisk Investigational Site Plantation Florida 33324
Novo Nordisk Investigational Site Roswell Georgia 30076
Novo Nordisk Investigational Site Honolulu Hawaii 96814
Novo Nordisk Investigational Site Chicago Illinois 60607
Novo Nordisk Investigational Site Evanston Illinois 60201-2477
Novo Nordisk Investigational Site Skokie Illinois 60077
Novo Nordisk Investigational Site Albany New York 12203
Novo Nordisk Investigational Site Endwell New York 13760
Novo Nordisk Investigational Site Chapel Hill North Carolina 27517
Novo Nordisk Investigational Site Greensboro North Carolina 27408
Novo Nordisk Investigational Site Hickory North Carolina 28601
Novo Nordisk Investigational Site Raleigh North Carolina 27609
Novo Nordisk Investigational Site Wilmington North Carolina 28401
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104-3317
Novo Nordisk Investigational Site Charleston South Carolina 29425
Novo Nordisk Investigational Site Mt. Pleasant South Carolina 29464
Novo Nordisk Investigational Site Knoxville Tennessee 37912
Novo Nordisk Investigational Site Austin Texas 78731
Novo Nordisk Investigational Site Dallas Texas 75226
Novo Nordisk Investigational Site Dallas Texas 75230
Novo Nordisk Investigational Site Dallas Texas 75231
Novo Nordisk Investigational Site Rockwall Texas 75032
Novo Nordisk Investigational Site Round Rock Texas 78681
Novo Nordisk Investigational Site St. George Utah 84790
Novo Nordisk Investigational Site Arlington Virginia 22206
Novo Nordisk Investigational Site Newport News Virginia 23606
Novo Nordisk Investigational Site Winchester Virginia 22601-3834
Novo Nordisk Investigational Site Olympia Washington 98502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03611582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 10, 2021 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03611582 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →